Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
Merck
Harvard Business School
McKinsey

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Litigation Details for Enzon Pharmaceutical v. Phoenix Pharm. Inc. (D. Del. 2004)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Enzon Pharmaceutical v. Phoenix Pharm. Inc. (D. Del. 2004)

Docket   Start Trial Date Filed 2004-09-21
Court District Court, D. Delaware Date Terminated 2006-03-06
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ENZON PHARMACEUTICALS INC.; PHOENIX PHARMACOLOGICS INC.
Patents 4,179,337
Attorneys Glenn Christopher Mandalas; Joseph Lucci; Josy W. Ingersoll; Karen Elizabeth Keller; Patrick Farley; Richard D. Kirk; Stephen C. Timmins
Firms Baird Mandalas Brockstedt LLC; Shaw Keller LLP; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Enzon Pharmaceutical v. Phoenix Pharm. Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .
Biologic Drugs cited in Enzon Pharmaceutical v. Phoenix Pharm. Inc.
The biologic drug covered by the patent cited in this case is   Start Trial .

Details for Enzon Pharmaceutical v. Phoenix Pharm. Inc. (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2005-07-01 33 Exhibit B in a manner similar to that described in U.S. 4,179,337, or U.S. 4,946,778, or any other technology or…make or con ceive inventions, whether or not patentable, soler or jointly with others du ring such employment…which is the basis for the Invention and Licensed Patents as defined under the License Agreement, and from…2004 6 March 2006 1:04-cv-01285 830 Patent None District Court, D. Delaware External link to document
2005-10-11 87 Exhibit 1 (56) References Cited U.S.` PATENT DOCUMENTS 4,179,337 1211979 Davisetn 435/181 4,609,546 911986…Medicine, 1987, 316(10), 589~596.\ (10) Patent No.: (45) Date of Patent: US 6,183,738 Bl Feb. 6,2001 Jaffe… humans than it does in mice Each of the patents, patent applications and publications described herein…tgglll\\\\\\\\\\m\u\\uu\ (12> United States Patent Clark (54) MODIFIED ARGININE DEIMINASE (75'…(US) Under 35 U.SWCn 154(1)), the term of this patent shall be extended for 0 daysn ( "‘ ) Notice External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
Baxter
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.